Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

In the short term, the 6.6% yield, coupled with favorable price action and low valuation ... considering the high demand for GLP-1 receptor agonists in the US. Until then, I see several headwinds ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

When was the Elden Ring Nightreign beta? The Lands Between beckons us once more for a standalone expansion that introduces a roguelike loop into FromSoftware’s formula. Playtests are the perfect ...